Ep 45 - Scott Brunner on Compounders vs. Big Pharma
Hims House
00:00
Regulatory Challenges in Compounding Practices
This chapter explores the intricate regulatory frameworks affecting compounded drugs, focusing on the 5% rule and MOUs in interstate shipments. It highlights the FDA's evolving stance on GLP-1 drugs and the implications for patient care and drug availability, along with the debates between pharmaceutical companies and compounding pharmacies. The discussion also examines the role of prescribers, recent shifts in FDA leadership, and how these elements interact with legislative strategies in the compounding field.
Transcript
Play full episode
